PRESS-RELEASE ·Filed Sep 11, 2026
Press release · Regulatory
Actionable Insight • Neutral
This is a routine scheduling announcement with no market-moving content. Traders should monitor the September 14 call for any material business updates, but no immediate action is warranted based on this filing alone.
Latest settled — T+20d
CLLS ▼ -35.52% at T+20d
NEUTRAL call -35.52% · α vs SPY -37.78% · entry $1.83 → $1.18
Latest observation: T+29 -47.27% FF3 residual α
T+1d
-12.02%
call -12.02% · α -11.56%
$1.61
settled 6w ago
T+5d
-17.49%
call -17.49% · α -19.14%
$1.51
settled 6w ago
T+20d
-35.52%
call -35.52% · α -37.78%
$1.18
settled 18d ago
T+60d
Pending
in 6w
Price Chart
Loading chart...
Executive Summary
Cellectis announced a conference call and webcast for September 14, 2026, to provide a business update. The press release contains no financial results, clinical data, or material corporate events — it is purely an administrative scheduling notice.
Key Facts
- Conference call scheduled for September 14, 2026 at 8:00 a.m. ET (English) and 9:00 a.m. ET (French)
- No financial results, clinical data, or material events disclosed in the press release
- Replay will be available on the company's website following the event
Financial Impact
No financial impact disclosed
Risk Factors
- No material information provided — the call could reveal negative news
- Clinical-stage biotech with no approved products carries inherent pipeline risk
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
85% bullish (13 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3360521 |
14 reports for CLLS
40% Hit rate @ T+60 Went positive at some point 4 of 6 best @ T+20▲ +35.52%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 6-K | $1.83 | awaiting T+60 | — | $0.9670 (+47.16%) |
Sep 11, 2026 6w ago | Press Release | $1.83 | awaiting T+60 | — | $0.9670 (−47.16%) |
Aug 6, 2026 11w ago | Press Release | $2.84 | awaiting T+60 | — | $0.9670 (−65.89%) |
Jun 29, 2026 17w ago | Court Ruling | $3.00 $1.43 | ▼ −52.33% | ▼ −55.32% | $0.9670 (−67.77%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $0.9670 (−65.83%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $0.9670 (−65.83%) |
Jun 11, 2026 19w ago | Press Release | $3.09 $3.24 | ▲ +4.85% | ▲ +0.46% | $0.9670 (−68.71%) |
Jun 9, 2026 19w ago | 6-K | $3.18 $3.32 | ▲ +4.40% | ▼ −2.18% | $0.9670 (−69.59%) |
May 12, 2026 23w ago | 6-K | $3.96 $2.69 | ▼ −32.07% | ▼ −36.45% | $0.9670 (−75.58%) |
May 4, 2026 25w ago | 6-K | $3.76 $2.85 | ▼ −24.20% | ▼ −26.94% | $0.9670 (−74.28%) |
Showing 10 of 14
US Market Status
Market Closed — Opens Wed (10h 42m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers